[go: up one dir, main page]

TR201106844T2 - Moksi̇floksasi̇n yaş granülasyonunda organi̇k solventleri̇n kullanimi. - Google Patents

Moksi̇floksasi̇n yaş granülasyonunda organi̇k solventleri̇n kullanimi.

Info

Publication number
TR201106844T2
TR201106844T2 TR2011/06844T TR201106844T TR201106844T2 TR 201106844 T2 TR201106844 T2 TR 201106844T2 TR 2011/06844 T TR2011/06844 T TR 2011/06844T TR 201106844 T TR201106844 T TR 201106844T TR 201106844 T2 TR201106844 T2 TR 201106844T2
Authority
TR
Turkey
Prior art keywords
moxifloxacin
granulation
age
organic solvents
organic solvent
Prior art date
Application number
TR2011/06844T
Other languages
English (en)
Inventor
Far�� Ferhat
Ko� F�Kret
S�Ylemez Serdar
Avci Recep
Original Assignee
Abd� �Brah�M �La� Sanay� Ve T�Caret Anon�M ��Rket�@
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40070762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201106844(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abd� �Brah�M �La� Sanay� Ve T�Caret Anon�M ��Rket�@ filed Critical Abd� �Brah�M �La� Sanay� Ve T�Caret Anon�M ��Rket�@
Publication of TR201106844T2 publication Critical patent/TR201106844T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Buluş, organik çözücü veya organik çözücü karışımları ile yaş granülasyon metodu kullanarak, dönüştürülemez anhidms moksifloksasin katı farmasötik formülasyonu elde etmeyi kapsar.
TR2011/06844T 2008-10-09 2008-10-09 Moksi̇floksasi̇n yaş granülasyonunda organi̇k solventleri̇n kullanimi. TR201106844T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/054141 WO2010041100A1 (en) 2008-10-09 2008-10-09 Using of organic solvents in wet granulation of moxifloxacin

Publications (1)

Publication Number Publication Date
TR201106844T2 true TR201106844T2 (tr) 2012-02-21

Family

ID=40070762

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2011/06844T TR201106844T2 (tr) 2008-10-09 2008-10-09 Moksi̇floksasi̇n yaş granülasyonunda organi̇k solventleri̇n kullanimi.

Country Status (12)

Country Link
US (1) US8314122B2 (tr)
EP (1) EP2349220B1 (tr)
JP (1) JP5461565B2 (tr)
CN (1) CN102176902B (tr)
BR (1) BRPI0823092A2 (tr)
EA (1) EA201170545A1 (tr)
ES (1) ES2391132T3 (tr)
MX (1) MX2011003731A (tr)
PL (1) PL2349220T3 (tr)
PT (1) PT2349220E (tr)
TR (1) TR201106844T2 (tr)
WO (1) WO2010041100A1 (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200907227A2 (tr) * 2009-09-18 2011-04-21 Bi̇lgi̇ç Mahmut Çözünürlüğü yüksek stabil mikronize granüller.
EP2491921A1 (en) * 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Conservation of anhydrous form of gemifloxacin
CN102204911B (zh) * 2011-03-25 2013-04-17 华润赛科药业有限责任公司 一种盐酸莫西沙星药物组合物及其制备方法
BRPI1106900A2 (pt) * 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
FR2992218B1 (fr) * 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
JP4334616B2 (ja) * 1994-09-22 2009-09-30 ナームローゼ・フエンノートチヤツプ・オルガノン 湿式粒状化による投与単位体を製造する方法
DE19546249A1 (de) 1995-12-12 1997-06-19 Bayer Ag Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
BR9915208A (pt) 1998-11-10 2001-07-31 Bayer Ag Preparado farmacêutico de moxifloxacina
US20060252789A1 (en) * 2002-10-31 2006-11-09 Sujay Biswas Amorphous moxifloxacin hydrochloride
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds
DE602004022646D1 (de) * 2003-04-09 2009-10-01 Reddys Lab Ltd Dr Kristalline form iii von wasserfreiem moxifloxacin-hydrochlorid und ein verfahren zu seiner herstellung
US20050031683A1 (en) 2003-08-04 2005-02-10 Ashish Kapoor Solid pharmaceutical composition
DE102005036195A1 (de) 2005-08-02 2007-02-08 Robert Bosch Gmbh Handwerkzeugmaschine
GB0612422D0 (en) * 2006-06-23 2006-08-02 Generics Uk Ltd Novel hydrate form

Also Published As

Publication number Publication date
EA201170545A1 (ru) 2012-01-30
MX2011003731A (es) 2011-08-03
PT2349220E (pt) 2012-10-11
ES2391132T3 (es) 2012-11-21
US20110198774A1 (en) 2011-08-18
CN102176902A (zh) 2011-09-07
WO2010041100A1 (en) 2010-04-15
CN102176902B (zh) 2012-10-31
JP2012505194A (ja) 2012-03-01
US8314122B2 (en) 2012-11-20
EP2349220B1 (en) 2012-07-25
JP5461565B2 (ja) 2014-04-02
BRPI0823092A2 (pt) 2015-09-29
EP2349220A1 (en) 2011-08-03
PL2349220T3 (pl) 2012-12-31

Similar Documents

Publication Publication Date Title
CR11861A (es) Compuestos organicos
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
DOP2011000172A (es) Compuestos organicos
ECSP11011184A (es) Compuestos orgánicos
DOP2011000176A (es) Compuestos organicos
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CL2008000156A1 (es) Gel estable hidrofilo en base a un polimero para aplicacion topica porque comprende quitosano disuelto en un solvente; proceso para obtener el gel para uso topico antes mencionado; uso del gel.
CY1117934T1 (el) Αντιβακτηριακες φαρμακευτικες συνθεσεις
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2015000829A1 (es) Inhibidores de histona desmetilasas
CL2013000104A1 (es) Compuestos derivados de heterociclicos nitrogenados sustituidos, agonistas del receptor ip; composicion farmaceutica; combinación farmaceutica; y uso para el tratamiento de la hipertension arterial pulmonar.
CL2011001333A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
EA201492011A1 (ru) Безводные фармацевтические составы для местного применения
CL2014001930A1 (es) Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2).
CL2012003564A1 (es) Compuestos derivados de heteroaril limidazolona :composición farmacéutica;uso de los compuestos para la inhibición de jak1,jak2 y jak3; y combinaciones farmacéuticas.
BRPI0908097A2 (pt) uso de pelo menos um composto, peptídeo, e, formulação farmacêutica.
CY1116111T1 (el) Τοπικη συνθεση για τη θεραπεια της ακτινικης κερατωσης
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
IN2015DN01315A (tr)
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
EP3572073C0 (en) FREEZE DRYING ABOVE COLLAPSING TEMPERATURE
BR112014009006B8 (pt) Compostos heterocíclicos e métodos de uso dos mesmos
BRPI0921654A2 (pt) formulação farmacêutica
TR201106844T2 (tr) Moksi̇floksasi̇n yaş granülasyonunda organi̇k solventleri̇n kullanimi.